EC finally confirms benefit of Takeda's pioglitazone
This article was originally published in Scrip
Executive Summary
The European Commission finally adopted the opinion of its CHMP that Takeda's antidiabetic pioglitazone is a valid option for certain patients with type 2 diabetes, removing the safety cloud over the product.